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Abstract: BACKGROUND: Crystalloid solutions leave the circulation quickly, whereas colloids remain
for hours, thus promoting hemodynamic stability. However, colloids are expensive and promote renal
toxicity in critical care patients. This study tested the hypothesis that goal-directed colloid adminis-
tration during elective abdominal surgery decreases 30-day major complications more than goal-directed
crystalloid administration. METHODS: In this parallel-arm double-blinded multicenter randomized trial,
adults having moderate- to high-risk open and laparoscopically assisted abdominal surgery with general
anesthesia were randomly assigned to Doppler-guided intraoperative volume replacement with 6% hy-
droxyethyl starch 130/0.4 (n = 523) or lactated Ringer’s solution (n = 534). The primary outcome was a
composite of serious postoperative cardiac, pulmonary, infectious, gastrointestinal, renal, and coagulation
complications that were assessed with a generalized estimating equation multivariate model. The primary
safety outcome was a change in serum creatinine concentration up to 6 months postoperatively, compared
to baseline concentrations. RESULTS: A total of 1,057 patients were included in the analysis. Patients
assigned to crystalloid received a median [quartile 1, quartile 3] amount of 3.2 l [2.3, 4.4] of crystalloid,
and patients assigned to colloid received 1.0 l [0.5, 1.5] of colloid and 1.8 l [1.2, 2.4] of crystalloid. The
estimated intention-to-treat common effect relative risk for the primary composite was 0.90 for colloids
versus crystalloids (95% CI: 0.65 to 1.23, P = 0.51), and 18% (91 of 523) of colloid patients and 20% (103
of 534) of crystalloid patients incurred at least one component of the primary outcome composite. There
was no evidence of renal toxicity at any time. CONCLUSIONS: Doppler-guided intraoperative hydrox-
yethyl starch administration did not significantly reduce a composite of serious complications. However,
there was also no indication of renal or other toxicity.
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ABSTRACT
Background: Crystalloid solutions leave the circulation quickly, whereas 
colloids remain for hours, thus promoting hemodynamic stability. However, 
colloids are expensive and promote renal toxicity in critical care patients. This 
study tested the hypothesis that goal-directed colloid administration during 
elective abdominal surgery decreases 30-day major complications more than 
goal-directed crystalloid administration.
Methods: In this parallel-arm double-blinded multicenter randomized trial, 
adults having moderate- to high-risk open and laparoscopically assisted 
abdominal surgery with general anesthesia were randomly assigned to 
Doppler-guided intraoperative volume replacement with 6% hydroxyethyl 
starch 130/0.4 (n = 523) or lactated Ringer’s solution (n = 534). The pri-
mary outcome was a composite of serious postoperative cardiac, pulmonary, 
infectious, gastrointestinal, renal, and coagulation complications that were 
assessed with a generalized estimating equation multivariate model. The pri-
mary safety outcome was a change in serum creatinine concentration up to 6 
months postoperatively, compared to baseline concentrations.
Results: A total of 1,057 patients were included in the analysis. Patients assigned 
to crystalloid received a median [quartile 1, quartile 3] amount of 3.2 l [2.3, 4.4] 
of crystalloid, and patients assigned to colloid received 1.0 l [0.5, 1.5] of colloid 
and 1.8 l [1.2, 2.4] of crystalloid. The estimated intention-to-treat common effect 
relative risk for the primary composite was 0.90 for colloids versus crystalloids 
(95% CI: 0.65 to 1.23, P = 0.51), and 18% (91 of 523) of colloid patients and 
20% (103 of 534) of crystalloid patients incurred at least one component of the 
primary outcome composite. There was no evidence of renal toxicity at any time.
Conclusions: Doppler-guided intraoperative hydroxyethyl starch admin-
istration did not significantly reduce a composite of serious complications. 
However, there was also no indication of renal or other toxicity.
(ANESTHESIOLOGY 2019; 130:728–44)
EDITOR’S PERSPECTIVE
What We Already Know about This Topic
• Crystalloid solutions leave the circulation quickly, whereas colloids 
remain for hours, thus promoting hemodynamic stability. However, 
colloids are expensive and promote renal toxicity in critical care 
patients. Whether goal-directed intraoperative tetrastarch colloid 
administration reduces complications or promotes renal injury 
remains unknown.
What This Article Tells Us That Is New
• In a large randomized trial comparing intraoperative goal-directed 
6% hydroxyethyl starch with goal-directed lactated Ringer’s solu-
tion in patients having major abdominal surgery, 6% hydroxyethyl 
starch reduced neither a composite of serious complications nor the 
duration of hospitalization. However, 6% hydroxyethyl starch did not 
cause acute or long-term renal toxicity.
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A key role for anesthesiologists is to maintain intraop-erative hemodynamic stability, a task that is compli-
cated by large fluid losses consequent to major surgery. 
Volume replacement is the major compensation for fluid 
loss. Crystalloid salt solutions are the most commonly used 
perioperative fluids because they are inexpensive, read-
ily available, and relatively nontoxic.1 However, crystal-
loid solutions start to leave the intravascular space within 
minutes, thereafter providing little hemodynamic support. 
Crystalloids also accumulate in tissues including lungs and 
incision sites, thus promoting edema, weight gain, and pro-
longed recovery.2–4
In contrast, colloids remain in the circulation for hours, 
thus promoting hemodynamic stability.5,6 Albumin was the 
original colloid volume replacement fluid and has been 
used since the 1940s.7 However, being a human product, 
albumin is expensive, and the supply is sometimes limited. 
Consequently, starch preparations are now by far the most 
commonly used colloid volume expander.8
In septic and critically ill patients, starch preparations 
cause renal injury and death,9–12 which has alarmed the 
European Medicines Agency13 and the U.S. Food and Drug 
Administration.14 Short-term use of starches has not been 
associated with renal toxicity,15 but their effectiveness and 
safety has yet to be evaluated in a robust perioperative 
trial.16 Furthermore, despite limited evidence worldwide, 
the issuing of IV fluid solutions to hospital departments has 
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changed in recent years to less colloids, particularly syn-
thetic solutions, and relatively more crystalloids, particularly 
buffered solutions.17,18
We therefore tested the primary hypothesis that a 30-day 
composite of serious complications is reduced by intraop-
erative administration of colloid (Voluven, Fresenius Kabi, 
Germany) versus crystalloid (lactated Ringer’s solution) in 
patients having moderate to high-risk open and laparoscop-
ically assisted abdominal surgery with general anesthesia. 
Our secondary hypothesis was that colloid administration 
reduces the primary composite outcome augmented by 
30-day all-cause mortality and hospital readmission and 
that colloid administration reduces a composite of minor 
complications. A tertiary hypothesis was that colloid admin-
istration reduces hospital length of stay. Our primary safety 
outcome was the change in serum creatinine concentration 
at various postoperative times.
A difficulty with comparing crystalloids and colloids is 
that volume requirements with each fluid differ. Because 
colloids remain intravascular longer than crystalloids, less 
fluid is required; but how much less depends on the specific 
colloid used and patient status, both of which vary over 
time. There is thus little justification in comparing specific 
volume ratios of crystalloids and colloids.19,20 We therefore 
used guided fluid management—based on optimizing car-
diovascular performance—to provide physiologically simi-
lar quantities of each fluid type throughout surgery.21–23
Materials and Methods
This trial was conducted with institutional review board 
approvals at three participating institutions and was regis-
tered at ClinicalTrials.gov (the trial was initially registered 
at NCT00517127 when it started at the Medical University 
of Vienna [Vienna, Austria] and was reregistered at 
NCT01195883 when the Cleveland Clinic [Cleveland, 
Ohio] joined the study). The trial was originally initiated at 
the Medical University of  Vienna and registered in 2007. After 
259 patients were enrolled in Vienna, in 2010, the Cleveland 
Clinic  and thereafter thereafter the Ohio State University 
(Columbus, Ohio) joined, the trial was reregistered by the 
Cleveland Clinic. With the reregistration in 2010, we also 
improved our study protocol. Especially individual parts of the 
major and minor complications were outlined in more detail. 
Thus, the second trial registration was more detailed than 
the first. Nevertheless, the same outcome data were prospec-
tively evaluated in all patients. Treatment was also consistent 
throughout the entire trial. Several sub-studies, which were 
performed at the Medical University of Vienna only, were in 
the initial trial registration and are not part of this manuscript.
Written consent was obtained from all patients. We eval-
uated patients scheduled for open or laparoscopic-assisted 
abdominal surgery expected to last at least 2 h who were 
age 18 to 80 yr, were American Society of Anesthesiologists 
(ASA) physical status I–III, and had a body mass index 
of less than 35 kg/m2. We excluded patients who had 
compromised kidney function (estimated creatinine clear-
ance less than 30 ml/min), estimated cardiac ejection frac-
tion less than 35%, severe chronic obstructive pulmonary 
disease, coagulopathies, or known esophageal or aortic 
abnormalities. Patients were given 5 to 7 ml/kg of lactated 
Ringer’s solution during anesthetic induction, followed by 
3 to 5 ml · kg−1 · h−1 of the solution for maintenance, nor-
malized to ideal body weight, throughout surgery.
Randomization and Masking
Shortly before induction of anesthesia, patients were ran-
domized 1:1, stratified by study site, to either goal-directed 
crystalloid administration (lactated Ringer’s solution) or 
goal-directed colloid administration (hydroxyethyl starch 
6% 130/0.4, Voluven, Fresenius Kabi,  Germany). The 
maximum dose of the colloid was 1,500 ml. We chose 
hydroxyethyl starch 130/0.4 because it was the newest 
starch and  associated with least renal or coagulation side 
effects. Furthermore, it was the most commonly used starch 
in Europe at the time. The randomization sequence was 
generated by the study statistician (E.J.M.) using the PLAN 
procedure in SAS statistical software (SAS Institute, USA) 
using randomly sized blocks and stratified by clinical site. 
Allocation was initially concealed with sequentially num-
bered sealed envelopes and then later in the study with a 
web-based system. A trained study coordinator at each site 
evaluated eligibility, obtained informed consent, and then 
on the day of surgery enrolled the participants by either 
opening the concealed envelope or accessing the web-based 
system. Intraoperative investigators and clinicians were not 
blinded to treatment. However, an observer strictly blinded 
to group assignment evaluated complications during hospi-
talization. Subsequently, a blinded investigator called patients 
30 days after surgery to assess postdischarge complications 
(primary outcome) and hospital readmission and vital status 
(secondary outcomes) described in this section below.
Intraoperative investigators administered the study flu-
ids strictly following our fluid algorithm. Intraoperative 
fluid administration was guided by esophageal Doppler 
(CardioQ, Deltex Medical Group PLC, United Kingdom) 
using a previously published algorithm.22 Based on stroke 
volume and corrected aortic flow time, boluses of 250 ml 
of the designated fluid were given over 5 min. Specifically, 
one fluid bolus was given preoperatively, and baseline fluid 
was started during induction of anesthesia. Fluid bolus as 
by randomization started after insertion of the esophageal 
Doppler probe.
Anesthesia management was standardized. We used bal-
anced anesthesia with inhalational agents. Epidural cathe-
ters were allowed. However, dosing had to be initiated at 
the end of the study for postoperative analgesia.
Target intraoperative hematocrit was maintained at 30% in 
patients having both cardiovascular disease and an age more 
than 65 yr and 28% in patients with one or the other, and 
26% in those with neither. Significant cardiovascular disease 
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was defined by previous myocardial infarction, angina, con-
gestive heart failure, cardiomyopathy, hypertension requiring 
treatment (or having a diastolic blood pressure exceeding 
90 mmHg), or peripheral vascular disease. In the postopera-
tive recovery unit we administered fluid at 2 ml · kg−1 · h−1, 
with additional fluid given as deemed clinically necessary. 
Postoperative analgesia was provided per institutional routine.
The primary outcome was postoperative morbid-
ity, defined by a composite of major complications, sim-
ilar to those used in many fluid management studies.24,25 
It included cardiac, pulmonary, infectious, gastrointestinal, 
renal, and coagulation complication.
Preplanned secondary outcomes included: (1) a com-
posite of minor complications including superficial inci-
sional infection as per Centers for Disease Control and 
Prevention (Atlanta, Georgia) criteria, postoperative fever, 
urinary tract infection, ST-segment change, nonventricular 
arrhythmias, hemodynamic disturbances requiring vasoactive 
drugs, unplanned intensive care unit admission, small perito-
neal pleural effusions, gastrointestinal paralysis, deep venous 
thrombosis, acute kidney injury, and transient neurologic 
complications; and (2) the primary composite augmented by 
readmission and mortality. We also evaluated the duration of 
hospitalization as a tertiary outcome. Our safety outcome was 
in-hospital serum creatinine concentrations and, as available, 
serum creatinine concentration up to 6 months postopera-
tively. (See appendix 2).
Statistical Analyses
The colloid and crystalloid groups were compared for bal-
ance on demographic and baseline characteristics using 
standard summary statistics and absolute standardized dif-
ference, defined as the difference in means or proportions 
divided by the pooled SD. Any variable with an absolute 
standardized difference greater than 0.20 was considered 
imbalanced and would be adjusted for in all analyses.
Primary Outcome 
The primary analysis was intention to treat so that all ran-
domized patients were included in all analyses. For the 
primary outcome of major complications, we assigned 
outcome values for missing outcome data (i.e., postran-
domization through 30 days) using last observation carried 
forward (n = 14 cases) when the outcome for a component 
of the composite was known at hospital discharge but not 
between discharge and 30 days. Five patients had a single 
major outcome component missing with all other compo-
nents being negative; for analysis, we assumed that they did 
not have had any complications.
We assessed the treatment effect on the major compli-
cations via a common effect “global” relative risk estimated 
across six outcomes of interest. In this multivariate anal-
ysis, each patient was represented once for each outcome 
event. The within-subject correlation among the outcomes 
was accounted for using a generalized estimating equation 
model with an unstructured working correlation matrix. 
Treatment-by-site interaction was assessed in a separated 
generalized estimating equations model.
As a sensitivity analysis we assessed the treatment effect 
on the collapsed composite of the six major complications 
(i.e., any vs. none) using a chi-square test. The Breslow–Day 
test was used to assess whether the treatment effect on the 
collapsed composite outcome differed across the three hos-
pitals. Due to the protocol change after 259 patients were 
enrolled, we also conducted a sensitivity analysis to assess 
whether there was an interaction effect between treatment 
group and the protocol change.
Secondary and Tertiary Outcomes 
We assessed the treatment effect on the collapsed composite 
of any minor complication and on a collapsed composite of 
any major complications plus 30-day mortality and 30-day 
readmission, each with a chi-square test. The minor com-
plication analysis was a per-protocol analysis because more 
than 10% of patients (n = 145) had at least one minor com-
ponent missing, making an intention-to-treat analysis with 
conservative assignment unrealistic.
Duration of hospitalization and readmission were ana-
lyzed as time to discharge alive and time to readmission, 
and the treatment effects were assessed using Cox propor-
tional hazards models. To avoid bias from considering early 
deaths as short hospitalizations and thus favorable lengths 
of stay, patients who died in the hospital were assigned the 
longest observed hospital stay of any patient and censored 
at that time (i.e., not discharged alive). Patients who died 
within 30 days after surgery were censored at the date of 
death for the time to readmission analysis. Because only 1% 
of patients died within 30 days, a competing risks analysis 
was unnecessary.
Safety Outcomes 
Because harm was reported in septic critical care patients 
during the course of our study,9–12 the Data Safety and 
Monitoring Board (Cleveland, Ohio)  added renal toxicity 
as a safety outcome. We compared colloids and crystalloids 
groups on the maximum postoperative serum creatinine 
concentration during hospitalization and within 6 months 
thereafter with analysis of covariance adjusted for the preop-
erative serum creatinine. Because serum creatinine concen-
trations were not normally distributed, we analyzed them on 
a log scale, with treatment effect reported as the ratio of geo-
metric means. We also assessed between-group differences in 
creatinine changes over time using linear mixed models to 
adjust for within-patient correlation: (1) over postoperative 
days 1 to 14 and (2) over postoperative months 1 to 6.
Interim Analyses 
We used a group-sequential design in which four interim 
analyses were planned with a maximum enrollment of 1,112 
patients, using the γ spending values of −4 for efficacy and 
−1 for futility. At the final analysis, primary outcome CI 
used the interim-adjusted α of 0.04.
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The significance criterion for each secondary outcome 
was P < 0.017 (i.e., 0.05/3, Bonferroni correction for two 
secondary outcomes and one tertiary outcome). For sim-
plicity of presentation, we refer to these adjusted intervals as 
95% CI throughout. SAS software version 9.4 for Windows 
(SAS Institute, USA) was used for analyses.
Power Analysis 
Our maximum sample size of 1,112 (including interim and 
final analyses) was based on being able to detect a risk reduc-
tion of 30 to 40% across the outcomes in our multivariate gen-
eralized estimating equation model with 80% power at the 
0.05 significance level. Based on our own pilot data of 259 
patients (enrolled under the initial study registration) and eval-
uated in blinded fashion, we assumed individual incidences for 
the outcomes of interest of the combined treatment groups 
ranging from 2 to 10% and within-subject correlations rang-
ing from about 0.05 to 0.30 across the outcomes. Detectable 
risk reduction for the planned sample size is expressed as a 
range because it depends on the degree of correlation among 
components of the composite, which was unknown in the trial 
design phase.
Results
Patients were enrolled between November 2006 and 
October 2016, mostly at the Cleveland Clinic and 
Medical University of Vienna. At the fourth interim anal-
ysis (n = 890, 80% of planned enrollment), there was no 
difference between crystalloid and colloid groups across 
the six major complications (intention-to-treat analysis, 
P = 0.40). The futility boundary was crossed so the study 
was stopped per protocol. While outcomes data on the ini-
tial 890 patients were being collected and analyzed, 219 
additional patients were randomized. We thus report results 
from 1,102 randomized patients. After 52 patients with-
drew, 1,057 patients remained for analysis, including 507 
from the Medical University of Vienna, 498 from Cleveland 
Clinic, and 45 from Ohio State University (figs. 1 and 2).
Fig. 1. Patient flow chart.
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Of 1,102 patients in total, 259 patients were enrolled 
under the initial protocol. Sixteen patients were lost to fol-
low-up after discharge, including 14 patients who had out-
comes evaluated at discharge: we carried forward their last 
observations for the primary analysis. Two others without 
discharge values (both in the crystalloid group) were assigned 
30-day outcomes under a conservative scenario. Only 10 
patients had laparoscopically assisted surgery, whereas the 
remainder of the patients had open abdominal surgery.
Patients given colloid and crystalloid were well balanced 
on baseline characteristics, so no covariable adjustment 
was needed in the analyses (table 1; appendices 3 and 9). 
The median [quartile 1, quartile 3] amount of crystalloid 
given to patients assigned to crystalloid was 3.2 l [2.3, 4.4]. 
Patients assigned to colloid were given 1.0 l [0.5, 1.5] of 
colloid and 1.8 l [1.2, 2.4] of crystalloid.
Appendix 4 lists the components of the primary and sec-
ondary composites, the incidence of each component, and 
the incidence of each composite. Figure 3 is a forest plot 
showing the primary outcome relative risks and individual 
group risks overall, by study site, and by component. In 
total, 18% (91 of 523) of colloid patients and 20% (103 of 
534) of crystalloid patients incurred at least one component 
of the primary outcome composite.
No difference was found between colloid and crystal-
loids on the primary outcome composite, with an estimated 
common effect relative risk across the six major complica-
tions for colloid versus crystalloid patients of 0.90 (95% CI, 
0.65 to 1.23), P = 0.51 (table 2; fig. 3). We also assessed the 
treatment effect on the collapsed composite of the major 
complications (any vs. none), with estimated relative risk 
of having any major complication of 0.90 (95% CI, 0.69 
to 1.18), P = 0.43 (table 2). No interactions were detected 
across the complication components or among sites, so that 
the treatment effect was not found to differ across compo-
nents of the composite of major complications or to vary 
by clinical site. Further, the treatment effect on the primary 
outcome composite did not vary by ASA group (III vs. II 
or lower), P = 0.99.
There was no interaction between before and after the 
protocol change on primary outcome (P = 0.37). For 
patients who were enrolled before the protocol change, the 
relative risk of the primary outcome for the colloid group 
compared with crystalloid was 1.13 (95% CI, 0.11 to 2.09), 
P ≥ 0.9; after the protocol change the estimated relative risk 
was 1.08 (95% CI, 0.86 to 1.36), P ≥ 0.9.
No treatment effect was found on the secondary out-
come of any minor complication, with relative risk (98.3% 
CI) of 0.95 (0.81 to 1.23; table  3), P = 0.42, in colloid 
versus crystalloid: incidence of any minor complication was 
48% for the colloid patients and 51% (appendix 5) for the 
crystalloid patients. Neither was there an effect of colloid 
versus crystalloid on the secondary composite outcome of 
any major complications (primary composite) plus 30-day 
mortality or 30-day readmission, with relative risk (98.3% 
CI) of 0.89 (0.69 to 1.14), P = 0.26.
Thirty-day mortality was 1.0% for colloid patients and 
0.8% for crystalloid patients, with estimated relative risk of 
1.28 (98.3% CI, 0.26 to 6.29) for colloid versus crystalloid, 
P = 0.71. The 30-day readmission rate was 11.9% in the 
colloid group and 12% in the crystalloid group. Finally, no 
difference was found between the randomized groups on 
length of hospital stay, with median [quartiles] length of 
hospital stay of 7 [5, 11] days for both groups (hazard ratio 
[98.3% CI] of 1.05 [0.90 to 1.21]), P = 0.45.
After adjusting for baseline serum creatinine, the ratio 
of geometric means for maximum creatinine during the 
hospital stay was 0.97 (95% CI, 0.93 to 1.01) for colloid 
versus crystalloid, P = 0.19. There was also no difference 
up to 6 months after discharge, with an estimated ratio of 
geometric means of 0.97 (95% CI, 0.93 to 1.02; fig.  4), 
P = 0.23. There were no creatinine differences between 
the groups over the initial 14 postoperative days (P = 0.84; 
appendices 5 and 6) or initial 6 months (P = 0.54, appen-
dices 7 and 8).
Fig. 2. Interim monitoring results for the primary analysis: 
common effect generalized estimating equation relative risk of 
colloid versus crystalloid across six postoperative major com-
plications. Group sequential futility boundary (pink region) was 
crossed at the fourth interim analysis (N = 890); the trial was 
therefore stopped for futility. While outcomes data on the initial 
890 patients were being collected and analyzed, 219 additional 
patients were randomized. We thus report results from 1,102 
randomized patients. After 52 patients withdrew, 1,057 patients 
remained for analysis. The vertical axis is the Z statistic corre-
sponding to the standardized treatment effect estimated at each 
interim analysis; negative values indicate efficacy of colloid (sig-
nificant if reaching lower blue region), whereas positive values 
indicate harm (significant if reaching upper blue region).
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Stage 1 acute kidney injury was observed in 20 
(3.9%) colloid patients and 12 (2.3%) crystalloid 
patients; stage 2 injury was observed in 1 (0.2%) col-
loid patient and 4 (0.8%) crystalloid patients; and there 
was no stage 3 acute kidney injury. Acute kidney injury 
did not differ significantly, with an estimated odds ratio 
of 1.33 (95% CI, 0.69 to 2.58, colloids vs. crystalloids, 
P = 0.40).
Table 1. Baseline and Intraoperative Characteristics (N = 1,057)
Variables Colloids (n = 523) Crystalloids (n = 534) ASD*
Age, yr 52 ± 16 52 ± 16 0.03
Body mass index, kg/m2 25.5 [22.3, 29.1] 25.5 [22.4, 28.6] 0.01
Female, no. (%) 242 (46) 268 (50) 0.08
ASA physical status, no. (%)   0.06
 I 54 (11) 7 46 (9)1  
 II 300 (58) 316 (59)  
 III 162 (32) 171 (32)  
Race (white), no. (%) 495 (95) 508 (95) 0.02
Medical history, no. (%)    
 Pulmonary disease 41 (8)9 38 (7)13 0.03
 Cardiovascular disease 142 (27)3 161 (30)2 0.07
 Neurologic disease 25 (5)20 23 (5)17 0.02
 Diabetes 40 (8)21 38 (7)16 0.02
 Insulin use 11 (2)21 7 (1)19 0.06
 History of PONV 43 (8)1 48 (9)1 0.03
 Alcohol (more than 25 drinks per week) 24 (5)49 29 (6)43 0.04
Smoking status   0.12
 No 271 (59)62 299 (63)58  
 Yes, currently 95 (21) 100 (21)  
 Yes, quit 95 (21) 77 (16)  
Preoperative bowel preparation   0.03
 Home 53 (10)4 56 (11)1  
 Hospital 115 (22) 112 (21)  
 None 351 (68) 365 (68)  
Preoperative lab    
 Creatinine, mg/dl 0.8 [0.7, 1.0]3 0.8 [0.7, 0.9]7 0.06
 Albumin, g/dl 4.4 [4.0, 5.0]99 4.4 [4.0, 5.1]113 0.05
 Hemoglobin, mg/dl 13.6 ± 5.43 13.2 ± 1.91 0.09
 Hematocrit, % 39.4 ± 5.13 39.4 ± 5.11 0.01
 Normotest/PT, s 103.0 [77.0, 121.0]230 100 [81, 121]246 0.03
 APTT STA, s 34.0 [30.6, 36.9]229 33.1 [30.7, 36.1]239 0.10
 Preoperative IV fluid per weight, ml/kg 6.0 [0, 7.7]26 6.2 [0, 7.8]28 0.02
Intraoperative variables    
 Duration of anesthesia, h 4.4 [3.4, 5.7] 4.5 [3.6, 5.7] 0.07
 Duration of surgery, h 3.4 [2.4, 4.5] 3.4 [2.5, 4.7] 0.08
 Crystalloid, l 1.8 [1.2, 2.4] 3.2 [2.3, 4.4] 0.70
 Colloid, l 1.0 [0.5, 1.5]2 0 [0, 0]10 2.62
 Number of boluses 4 [2, 6] 5 [3, 8] 0.44
 Blood given, ml 0 [0, 0]8 0 [0, 0]10 0.13
 Estimated blood lost, ml 250 [100, 500]1 250 [100, 500]1 0.05
 Estimated urine output, ml 320 [195, 500]4 340 [200, 500]6 0.04
 Other fluids, ml 100 [0, 400]36 100 [0, 450]40 0.05
 Net fluids, l 2.67 [1.85, 3.45]3 3.07 [2.15, 4.21]6 0.34
 TWA MAP, mmHg 80 ± 934 80 ± 934 0.01
 End-tidal PCO
2
, mmHg 34.6 ± 2.435 34.3 ± 2.335 0.16
 Final intraoperative core temperature, °C 36.8 ± 3.035 36.6 ± 2.836 0.04
 TWA  FIO
2
, % 68 ± 1534 69 ± 2035 0.03
 MAC, % 2.2 ± 2.637 2.1 ± 1.936 0.03
 Phenylephrine, mg† 0.10 [0, 0.40] 0.10 [0, 0.50] 0.15
Summary statistics are presented as percentages of patients, means ± SD, or median [quartile 1, quartile 3], respectively. Superscript numbers represent number of missing values. 
Net fluids: sum of colloids, crystalloids, and other fluids minus estimated urine output. 
*Absolute standardized difference (ASD): absolute difference in means or proportions divided by the pooled SD; ASD values of 0.2, 0.5, and 0.8 represent small, median, and large 
differences. 
†Only three patients at Cleveland Clinic and one patient at the Medical University of Vienna were given epinephrine; one patient at Cleveland Clinic was given vasopressin; no patients 
at Cleveland Clinic were given norepinephrine.
APTT, partial thromboplastine time; ASA, American Society of Anesthesiologists; ASD, absolute standardized difference; FIO
2
, fraction inspired oxygen concentration; MAC, minimum 
alveolar concentration, a measure of anesthetic dose; MAP, mean arterial pressure; PCO
2
, end-tidal partial pressure of carbon dioxide; PONV, postoperative nausea and vomiting; PT, 
prothrommbin time; TWA, time weighted average.
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Discussion
The incidence of a composite of serious complications did 
not differ significantly for goal-directed crystalloids and col-
loids; results were similar when the primary composite was 
augmented by hospital readmission and death. There was 
also no difference in a composite of minor complications. 
Our results thus do not support superiority of hydroxyethyl 
starch colloids over less-expensive crystalloids in terms of 
major and minor complications.
A recent consensus statement by the European Society 
of Intensive Care Medicine recommended using colloids in 
critically ill patients only in the context of clinical trials.26 
Regulatory authorities in both Europe13 and the United 
Fig. 3. Forest plot with estimated relative risks for primary analysis: overall (common effect generalized estimating equation multivariate 
model) and by component. Estimated treatment effect of colloids versus crystalloids on the composite outcome of any major complications 
and individual components of the composite outcome. Relative risk (RR) was not estimated for Ohio State University patients by themselves 
due to low incidence, but Ohio State University was included in the “all patients” analyses.
Table 2. Primary Outcome: Effect of Colloids versus Crystalloids on Composite Endpoint Vector of Six Types of Major Postoperative 
Complications (N = 1,057)
Analysis
Primary Analysis Common  
Effect GEE Model*
Sensitivity Analysis Collapsed Composite  
(Any vs. None)†
Relative Risk (95% CI) 
Colloid/Crystalloid P Value
Relative Risk (95% CI) 
Colloid/Crystalloid P Value
All patients (N = 1,057) 0.90 (0.65 to 1.23) 0.51 0.90 (0.69 to 1.18) 0.43
Cleveland Clinic only (n = 498) 0.82 (0.49 to 1.38) 0.45 0.74 (0.46 to 1.20) 0.20
Medical University of Vienna only (n = 507) 0.95 (0.64 to 1.43) 0.82 0.96 (0.69 to 1.32) 0.77
Ohio State University only (n = 52) ‡ ‡ ‡ ‡
For two crystalloid patients from the Medical University of Vienna with completely missing data, all components were assigned “no event.” Treatment-by-site interaction was 0.49 
(nonsignificant) for Cleveland Clinic and Medical University of Vienna. Sensitivity analysis: primary analysis when adjusting for clinical site gives relative risk of 0.89 (0.65 to 1.22), 
P = 0.46. CI adjusts for interim monitoring on the primary outcome.
*Common effect “global” relative risk across the six major complications was estimated using a generalized estimating equation model with six records/patient (one/component) 
and unstructured working correlation matrix. Within-site analysis for the Medical University of Vienna used a compound symmetry correlation structure to avoid convergence issues. 
†Collapsed composite (any versus none) of having any major complications was assessed using a chi-square test. 
‡Relative risk was not estimated for Ohio State University by itself due to low incidence, but Ohio State University was included in the “all patients” analyses.
GEE, generalized estimating equations.
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States14 have issued cautions about the use of hydroxyethyl 
starch solutions in patients with sepsis, burn injuries, or crit-
ical illness. However, the perioperative period differs in that 
even patients having major surgery are generally less fragile 
than critical care patients and are rarely septic. Furthermore, 
low doses of colloids are usually given over relatively short 
periods. Perhaps consequently, we saw no evidence that 
colloid administration provoked renal injury during hospi-
talization, at least as estimated by serum creatinine concen-
tration. There were also no evidence of renal injury up to 
6 months postoperatively, although late creatinine measure-
ments were not required by protocol and thus available in 
only a small fraction of patients. Use of hydroxyethyl starch 
130/0.4 thus appears to be safe from a renal perspective in 
noncardiac surgery patients.
Our results are consistent with previous small periopera-
tive studies27 and with meta-analyses of previous studies.28,29 
As in our study, Yates et al.30 concluded that there is no ben-
efit in using hydroxyethyl starch over using crystalloids. In 
202 patients undergoing colorectal surgery, no difference 
was seen in the number of patients who suffered gastro-
intestinal morbidity on postoperative day 5 (30% in the 
hydroxyethyl starch group vs. 32% in the crystalloid group; 
adjusted odds ratio  0.96 [0.52 to 1.77]). No difference 
in the incidence of postoperative complications was seen 
between the groups. However, crystalloid patients received 
significantly larger amounts of fluid.30
However, a recent trial of 160 noncardiac surgical 
patients who were randomized to goal-directed crys-
talloid or colloid reports lower postoperative morbidity 
scores in patients assigned to colloids, along with fewer 
major and minor complications.31 Ours as well as their 
study used similar baseline infusion rates, and even the 
total amount study fluid administered as per protocol was 
comparable in the two studies. However, Joosten et al.31 
used large amounts of rescue colloids for hemodynamic 
stability, especially in the crystalloid group. This might 
have affected the overall administered fluid amount, 
which resulted in a greater difference of fluid given 
between the two groups. Despite the fact that both trials 
enrolled open abdominal surgical patients, our patients 
were probably slightly healthier and had less severe and 
somewhat shorter surgery. Our study patients had gen-
eral anesthesia while Joosten et al.31 allowed general and 
regional anesthesia. Although there are these method-
ologic differences, it is unclear why their results should 
differ from those in our 1,057 patients. The most likely 
assumption is that a study with  just 160 patients and 
variability in patient population and anesthesia manage-
ment was underpowered.
Feldheiser et al.32 showed that goal-directed colloidal 
administration is associated with better hemodynamic sta-
bility. Interestingly, stroke volume and cardiac output were 
improved, but not mean arterial pressure which might be an 
important predictor for myocardial injury after noncardiac 
surgery. 
Of note, in our study we saw a smaller number of cardiac 
events in patients receiving colloids. We had one colloid 
and eight crystalloid patients with cardiac events, which is 
too small a number to draw any conclusions. However, it 
Table 3. Secondary Outcomes: Comparison between Colloid 
and Crystalloid Patients on Secondary Outcomes
Treatment Effect 
(98.3% CI;  
Colloid vs.  
Crystalloid)* P Value
Secondary outcome   
 Primary composite plus 30-day readmission 
and death (n = 1,043)
0.89 (0.69 to 1.14)† 0.26
   Readmission within 30 days (n = 1,057)‡ 1.0 (0.65 to 1.52)§ 0.99
   30-day mortality (n = 1,057) 1.28 (0.26 to 6.29)† 0.71
 Any minor complication   
   All patients (n = 912) 0.95 (0.81 to 1.23)† 0.42
   CCF only (n = 480) 1.04 (0.80 to 1.35)† 0.74
   Vienna only (n = 389) 0.87 (0.71 to 1.06)† 0.09
  OSU only (n = 43) 1.18 (0.48 to 2.91)† 0.66
Tertiary outcome   
 Hospital length of stay (n = 1,057)∥ 1.05 (0.90 to 1.21)§ 0.45
*CI values are actually 98.3% in this table: Bonferroni correction for three outcomes 
(primary composite plus 30-day readmission and death, any minor complication and 
hospital length of stay). 
†Relative risk. 
‡The outcome was time to readmission and 10 dead patients were treated as cen-
sored at postoperative 30 days. 
§Hazard ratio. 
∥The outcome was time to discharge alive (hospital stay) and six dead patients in 
hospital were assigned to the longest observed hospital stay.
CCF, Cleveland Clinic Foundation; OSU, Ohio State University. 
Fig. 4. Box plots of preoperative serum creatinine concen-
tration and maximum postoperative serum creatinine before 
hospital discharge and within 6 months. Postdischarge length 
of follow-up across patients is presented as means ± SDs. No 
differences were found.
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has been shown recently that perioperative hypotension is 
associated with myocardial injury after noncardiac surgery.33 
Thus, better hemodynamic stability with colloids might 
result in improved cardiac outcome.
There remains considerable controversy over the ideal 
amount of fluid to be given during various types of sur-
gery, and there is considerable variation from site to site. 
Nonetheless, there is some consensus that goal-directed 
management is most likely to target the best dose in individ-
ual patients,34 although results are not entirely consistent.30,35 
An important feature of our trial is thus that goal-directed 
fluid management was used in all patients. Titrating fluid 
replacement to stroke volume not only provided compara-
ble physiologic amounts of each fluid throughout surgery, 
but also provided the right amounts of each presumably at 
the correct times.32,36–38
We used a baseline infusion rate of approximately 4 ml kg−1 
h−1 lactated Ringer’s solution. Crystalloid patients received on 
average five fluid boluses, and colloid patients received four 
fluid boluses. Thus, the total amount of fluids was similar in 
our two study groups. The amount of vasopressors was slightly 
but not significantly higher in patients receiving crystalloids.
Independent of Doppler guidance, the modest amount 
of fluid given—about 3 l over 4.5 h—is consistent with 
the current approach to fluid restriction. We used lac-
tated Ringer’s as our crystalloid as it is perhaps the most 
commonly used intraoperative balanced salt solution and, 
unlike normal saline, does not promote hyperchloremic 
acidosis.39,40
We selected hydroxyethyl starch 130/0.4, which is a 
third-generation colloid that is thought to cause less renal 
injury and coagulopathy than older starch preparations.41–43 
We avoided albumin because it is expensive and some-
times in short supply, although recent research suggests that 
human albumin protects the endothelial surface layer and 
might thus reduce interstitial edema.44
Colloid solutions are usually given to patients having 
large operations in which there is substantial volume loss. 
We thus restricted enrollment to patients having moder-
ate to major open or laparoscopically assisted abdominal 
surgery, those most likely to require substantial volume 
replacement. In fact, only a minimal number of our 
patients (10 patients) had laparoscopically assisted sur-
gery. Our results thus apply to general surgical patients 
likely to be given colloids. Our patient population was 
relatively healthy, with the majority of patients having an 
ASA physical status of II, a mean age of around 50 yr, and 
a body mass index near 25 kg/m2. It remains possible that 
starch solutions are more effective and/or more toxic in 
patients having significant cardiac or renal comorbidities, 
in older patients, or in obese patients. All of our patients 
had major surgery, but it remains possible that patients 
having the most invasive operations respond differently, 
including those having cardiac, major trauma, or transplant 
surgery with significant blood loss. The dose of colloid 
was approximately 1 l over 3 h, which is moderate consid-
ering that the maximum recommended dose is 33 ml/kg 
per 24 h. During the study, results of a major trial became 
available and showed that large volumes of colloid given 
over a period of days in critical care patients promoted 
renal toxicity.10 Consequent concerns slowed enrollment 
in Europe for several years. A resulting limitation of our 
trial is that enrollment lasted for an 11-yr period—a slow 
recruitment rate at a time of major changes in the under-
standing and practices of fluid resuscitation along with 
improvements in surgical practice. Because the trial was 
randomized, background changes in practice do not con-
stitute bias. However, to the extent that practice changes, 
results may be less relevant to current patients than the 
ones who enrolled in our trial earlier. For example, stroke 
volume is now more often used to guide fluid adminis-
tration than correct flow time. However, it seems unlikely 
that practice changes account for our results or that a new 
trial would identify substantial benefit or toxicity in similar 
patients. Despite the long enrollment period, there were 
no substantive changes to the protocol or outcomes. Our 
study demonstrates the difficulties of large randomized 
trials and the fact that not only funding or lack thereof 
but also the regulatory environment can effect enrollment. 
The colloid we studied is but one of several; it remains 
approved by both the U.S. Food and Drug Administration 
and the European Medicines Agency. Naturally, results 
might differ with alternative colloids.
Another limitation is that clinicians knew which fluid 
the patients were getting, which could have led to ascer-
tainment bias influencing additional fluid management by 
clinicians. However, fluids were given by research fellows 
and was based on strict criteria. Outcomes were evaluated 
by a separate team of investigators who were blinded to 
fluid allocation and intraoperative management.
In summary, Doppler-guided intraoperative hydroxyethyl 
starch administration did not reduce composites of serious 
complications. Nor did hydroxyethyl starch reduce the 
duration of hospitalization, but there was also no indication 
of renal or other toxicity. Because starch colloids are more 
expensive than crystalloids and apparently do not reduce 
perioperative complications, they should be used sparingly 
in surgical patients.
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Appendix 2. Definition of Major Complications
Organ Systems Complications
Cardiac Acute heart failure, myocardial infarction, ventricular arrhythmia
Pulmonary Pulmonary embolism, pulmonary edema, respiratory failure, pneumonia
Gastrointestinal Bowel and surgical anastomosis stricture/obstruction or anastomotic leak, internal or external fistulas, peritoneal effusions
Renal Dialysis
Infections Deep or organ/space surgical site infection, sepsis
Coagulation Bleeding
Requirements for Major Complications
Major Complications Requirements for Acceptance
Deep or organ/space surgical site infection CDC criteria (see below)
Sepsis Positive blood culture and at least two of the following: hypo- or hyperthermia, tachycardia, tachypnea, leukopenia/leuko-
cytosis ± DIC or multiorgan dysfunction
Bowel and surgical anastomosis stricture/
obstruction or anastomotic leak
Requiring surgical intervention
Ileus Requiring surgical intervention
Bleeding Requiring transfusion of more than four units and/or surgical intervention during the postoperative follow-up period
Large peritoneal/pleural effusion Diagnosed by x-ray, ultrasound, and/or aspiration and requiring chest tube, surgery, or ICU admission
Internal or external fistula formation Requiring intervention
Pulmonary emboli Sudden death or confirmation by V–Q scan showing high probability for pulmonary emboli, spiral CT scan or pulmonary 
arteriogram
Pulmonary edema and congestive heart 
failure
Shortness of breath, crepitation, peripheral edema, third heart sound, and radiologic signs (cardiomegaly, interstitial 
edema, alveolar edema) requiring medical treatment with diuretics
Acute heart failure Requiring inotropic therapy within 72 h of surgery
Myocardial infarction ECG changes and/or elevated myocardial enzymes (cTn-T ≥ 0.03 and/or CK ≥ 170IU and MB ≥ 5%)
Ventricular arrhythmias ECG changes requiring medical treatment and/or electroconversion
Renal failure Requiring dialysis
Respiratory failure Requiring intubation for more than 3 days
Pneumonia New infiltrate on CXR combined with two of the following: temperature > 38°C, leukocytosis, and positive sputum or 
bronchial culture
CDC, Centers for Disease Control and Prevention; CK, creatine kinase; CT, computed tomography; cTn-T, cardiac troponin; CXR, chest X-ray; DIC, disseminated intravascular coagu-
lation; ECG, electrocardiogram; ICU, intensive care unit; MB, muscle/brain; V–Q, ventilation perfusion.
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Appendix 3. Preoperative Medications, Primary Diagnosis, 





(N = 534) ASD*
Preoperative medication, no. (%)    
 α-Blocker 11 (2)27 17 (3)23 0.07
 Central α-agonists 2 (0)27 1 (0)22 0.04
 β-Blocker 57 (11)26 68 (13)22 0.05
 β-Agonist 11 (2)26 8 (2)22 0.05
 Peripheral α-agonists 2 (0)26 1 (0)22 0.04
 Nitrates 4 (1)26 4 (1)23 0.00
 Opioids 80 (16)26 74 (14)23 0.05
 Ace inhibitor 86 (17)27 80 (16)22 0.05
 Calcium antagonist 30 (6)26 36 (7)22 0.04
 Corticosteroids 38 (8)26 36 (7)22 0.02
 Antidiabetics 25 (5)26 29 (6)22 0.03
 Insulin 12 (2)26 8 (2)23 0.06
Primary diagnosis, no. (%)    
 Cancer 161 (52) 146 (48)  
 Ulcerative colitis/proctitis 82 (54) 70 (46)  
 Liver metastases 59 (53) 52 (47)  
 Crohn’s disease 39 (45) 47 (55)  
 Other intestinal diseases 40 (49) 41 (51)  
 Tumor 42 (53) 38 (48)  
 Diverticulitis 24 (62) 15 (38)  
 Fistula 13 (39) 20 (61)  
 Other liver diseases 9 (27) 24 (73)  
 Enteritis/enterocolitis 14 (50) 14 (50)  
 Pancreatitis 16 (64) 9 (36)  
 Other pancreas diseases 8 (73) 3 (27)  
 Gynecology diseases 4 (40) 6 (60)  
 Hernia 4 (50) 4 (50)  
 Gallbladder diseases 2 (29) 5 (71)  
 Bowel obstruction 1 (17) 5 (83)  
 Others 16 (40) 24 (60)  
Type of surgery (NOT mutually exclusive), no. (%)
 Liver resection 125 (24) 113 (21) 0.07
 Ileostomy 113 (22) 129 (24) 0.06
 Colectomy 108 (21) 123 (23) 0.06
 Pancreatectomy 56 (11) 70 (13) 0.07
 Pancoduodenectomy 37 (7) 43 (8) 0.04
 Proctectomy 37 (7) 35 (7) 0.02
 Hysterectomy 14 (3) 17 (3) 0.03
 Cholecystectomy 13 (2) 10 (2) 0.04
 Lymphadenectomy 4 (1) 4 (1) 0.00
 Nephrectomy 3 (1) 2 (0) 0.03
 Splenectomy 11 (2) 8 (2) 0.05
 Other resection 80 (15) 70 (13) 0.06
 Lap exploratory 72 (14) 73 (14) 0.00
 Rectal surgery 8 (2) 14 (3) 0.08
 Anastomosis 51 (10) 62 (12) 0.06
 Closure colostomy 18 (3) 17 (3) 0.01
 Bowel resection 16 (3) 9 (2) 0.09
 Sigma resection 11 (2) 10 (2) 0.02
 Hernia repair 10 (2) 5 (1) 0.08
Summary statistics are presented as percentages of patients. Superscript number 
represents number of missing values.
*Absolute standardized difference (ASD): absolute difference in means or propor-
tions divided by the pooled SD; ASDs of 0.2, 0.5, and 0.8 represent small, median, 
and large differences.
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Appendix 4. Incidence of Components of Postoperative Complications (N = 1,057)














Major complications  
 Cardiac 0 (0) 8 (2)2 1 (< 1)6 1 (< 1)9 1 (< 1)6 8 (2)10
  Acute heart failure       
  Myocardial infarction       
  Ventricular arrhythmia       
 Pulmonary 16 (3) 17 (3)2 1 (< 1)6 7 (1)9 17 (3)6 24 (5)10
  Pulmonary embolism       
  Pulmonary edema       
  Respiratory failure       
  Pneumonia       
  Pulmonary pleural effusion       
 Gastrointestinal 35 (7) 41 (8)2 6 (1)6 11 (2)9 41 (8)6 51 (10)10
  Bowel and surgical anastomosis, stricture/
obstruction or anastomotic leak
      
  Internal or external fistulas       
  Peritoneal effusions       
Renal (requiring dialysis) 2 (< 1) 2 (< 1)2 0 (0)6 2 (< 1)9 2 (< 1)6 4 (1)10
 Infections 40 (8) 40 (8)2 22 (4)6 20 (4)9 59 (11)6 58 (11)10
  Deep or organ/space surgical site infection       
  Sepsis       
 Coagulation (bleeding) 14 (3) 10 (2)2 2 (< 1)6 2 (< 1)9 16 (3)6 12 (2)10
Minor complications  
 Unplanned ICU admission 20 (4) 33 (6)2 3 (1)6 3 (1)9 22 (4)6 36 (7)10
 Minor unplanned operation 24 (5)16 18 (3)12 5 (1)21 5 (1)23 29 (6)28 23 (5)29
 Cardiac 32 (6) 45 (8)2 4 (1)100 2 (< 1)101 35 (8)95 46 (10)94
  Ischemia       
  Nonventricular Arrhythmia       
  Hemodynamic disturbances       
 Pulmonary effusion 35 (7)11 44 (8)9 4 (1)6 4 (1)9 38 (8)17 46 (9)17
 Deep venous thrombosis 2 (< 1) 2 (< 1)2 0 (0)6 6 (1)10 2 (< 1)6 7 (1)11
 Gastrointestinal 65 (12) 94 (18)2 12 (2)6 11 (2)9 75 (15)6 103 (20)10
  Effusion       
  Gut paralysis       
 Progressive renal insufficiency 2 (< 1) 4 (1)2 2 (< 1)6 3 (1)9 4 (1)6 7 (1)10
 Infection 100 (19)1 122 (23)2 46 (9)6 40 (8)9 139 (27)6 151 (29)10
  Superficial       
  Fever       
  Cystitis or urinary tract infection       
 Transient neurologic 3 (1) 7 (1)2 0 (0)6 1 (< 1)9 3 (1)6 8 (2)10
 Any major morbidity 70 (13) 76 (14)2 28 (6)6 33 (7)9 91 (18)6 103 (20)10
 Any minor morbidity 173(34)11 202 (38)6 59 (15)102 58 (14)103 214 (48)76 234 (51)71
Superscript numbers represent the number of missing values. Pulmonary pleural effusion was not asked on the old version of the case report form for 22 and 23 patients at discharge 
and 30-day follow-up, respectively. We assumed that those patients did not have pulmonary pleural effusion given the evidence that they did not have other pulmonary complications. 
Unplanned operation was not asked on the old version of the case report form for 22 and 17 patients at discharge and 30-day follow-up, respectively. Those were reported as missing 
in the above table.
*In total, 15 patients in crystalloid group and 17 patients in the colloid group died during hospital stays < 30 days or stayed in hospital for > 30 days; therefore, the 30-day follow-up 
was not done.
ICU, intensive care unit; POD, postoperative day.
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Appendix 6. Box Plots of Maximum Postoperative 
Serum Creatinine Concentrations from 
Postoperative Days 1 to 14
Bottoms and tops of the boxes are 25th and 75th percentiles, 
the middle line is the median, and the whiskers extend to the 
smaller of the end of the data (minimum or maximum) 
or 1.5 interquartile ranges beyond the top or bottom of box. 
Creatinine values between 0.5 and 1.4 mg/dl are generally 
considered to be in the normal range.
Appendix 5. Summary of Preoperative and Serum 
Creatinine Concentrations from Postoperative Days 1 to 14
Creatinine (mg/dl) N
Colloids  
(n = 523) N
Crystalloids  
(n = 534)
Preoperative 520 0.85 [0.73, 0.97] 527 0.83 [0.73, 0.94]
Maximum postoperative 
before discharge
521 0.83 [0.71, 1.00] 527 0.85 [0.71, 1.00]
POD 1 476 0.79 [0.67, 0.94] 493 0.77 [0.66,0.92]
POD 2 437 0.74 [0.62, 0.90] 431 0.75 [0.63, 0.87]
POD 3 341 0.75 [0.61, 0.88] 373 0.73 [0.60, 0.85]
POD 4 316 0.73 [0.61, 0.88] 341 0.74 [0.60, 0.86]
POD 5 259 0.72 [0.61, 0.86] 263 0.74 [0.62, 0.87]
POD 6 195 0.75 [0.61, 0.88] 204 0.76 [0.64, 0.91]
POD 7 170 0.74 [0.59, 0.88] 175 0.75 [0.62, 0.88]
POD 8 115 0.76 [0.65, 0.92] 110 0.75 [0.62, 0.92]
POD 9 101 0.78 [0.64, 0.92] 95 0.77 [0.66, 0.96]
POD 10 89 0.76 [0.61, 0.97] 99 0.75 [0.63, 1.00]
POD 11 64 0.76 [0.62, 0.92] 76 0.74 [0.62, 0.88]
POD 12 65 0.75 [0.62, 0.93] 52 0.77 [0.65, 0.94]
POD 13 43 0.82 [0.56, 0.96] 59 0.71 [0.59, 0.82]
POD 14 45 0.82 [0.66, 0.96] 45 0.72 [0.63, 0.92]
Numbers in brackets indicate range. POD, postoperative day.
Appendix 7. Summary of Preoperative and Maximum 




(n = 523) N
Crystalloids  
(n = 534)
Preoperative 520 0.85 [0.73, 0.97] 527 0.83 [0.73, 0.94]
Maximum postoperative 
within 6 months
521 0.87 [0.73, 1.06] 529 0.87 [0.75, 1.05]
Within 1 month 521 0.85 [0.72, 1.01] 529 0.85 [0.72, 1.02]
1 to 2 months 152 0.84 [0.72, 1.04] 177 0.84 [0.73, 0.96]
2 to 3 months 71 0.78 [0.70, 1.04] 87 0.80 [0.70, 0.93]
3 to 4 months 34 0.83 [0.75, 0.98] 44 0.78 [0.72, 0.93]
4 to 5 months 21 0.83 [0.72, 0.94] 18 0.71 [0.63, 0.79]
5 to 6 months 12 0.84 [0.73, 1.00] 3 0.62 [0.54, 0.73]
The data are number of patients (n) and median [quartile 1, quartile 3].
Appendix 8. Box Plots of Maximum Postoperative 
Serum Creatinine Concentrations from 
Postoperative Months 1 to 6
Bottoms and tops of boxes are 25th and 75th percentiles, the 
middle line is the median, and the whiskers extend to the 
smaller of the end of the data (minimum or maximum) 
or 1.5 interquartile ranges beyond the top or bottom of box. 
Creatinine values between 0.5 and 1.4 mg/dl are generally 
considered to be in the normal range. Sample size for each 
period for colloids and crystalloids is as follows (see appen-
dix 7): surgery to 1 month (521, 529), 1 to 2 months (152, 
177), 2 to 3 months (71, 87), 3 to 4 months (34, 44), 4 to 5 
months (21, 18), and 5 to 6 months (12, 3).
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Appendix 9-1. Baseline and Intraoperative Characteristics 





(n = 131) ASD*
Age, yr 55.1 ± 14.1 56.2 ± 12.8 0.08
Body mass index, kg/m2 25.7 ± 4.8 29.6 ± 45.6 0.12
Female, no. (%) 57 (45) 70 (53) 0.18
ASA physical status, no. (%)   0.21
 I 30 (23) 25 (19)  
 II 80 (63) 94 (72)  
 III 18 (14) 12 (9)  
Race (white), no. (%) 126 (98) 130 (99) 0.08
Medical history, no. (%)    
 Pulmonary disease 7 (6)4 7 (6)6 0.002
 Cardiovascular disease 44 (35)2 47 (36)2 0.03
 Neurologic disease 7 (6)20 4 (4)17 0.14
 Diabetes 11 (10)20 14 (12)16  
 Insulin use 2 (2)21 0 (0)19 0.20
 History of PONV 14 (11) 13 (10) 0.03
 Alcohol (more than 25 
drinks per week)
0 (0)48 2 (2)42 0.21
 Smoking status   0.02
  No 43 (64)61 47 (64)57  
  Yes, currently 18 (27) 20 (27)  
  Yes, quit 6 (9) 7 (9)  
Preoperative bowel preparation   0.13
 Home 1 (1) 0 (0)  
 Hospital 37 (29) 36 (27)  
 None 90 (70) 95 (73)  
Preoperative lab    
 Creatinine, mg/dl 0.9 [0.8, 1.0] 0.9 [0.8, 0.9] 0.27
 Albumin, g/dl 4.6 [4.0, 43.1]7 4.5 [3.9, 42.5]10 0.05
 Hemoglobin, gm/dl 13.4 ± 2.8 13.3 ± 2.2 0.05
 Hematocrit, % 39.1 ± 4.2 39.2 ± 4.0 0.03
 Normotest/PT, s 114.5 [98, 130] 113 [97, 131]1 0.01
 APTT STA, s 35.2 [32.7, 37.9] 35.0 [32.1, 37.6]2 0.12
 Preoperative IV fluid per 
weight, ml/kg
6.7 [5.8, 7.9] 6.8 [6.1, 7.9] 0.11
Intraoperative variables    
 Duration of anesthesia, h 4.6 [3.5, 5.7] 4.8 [4.0, 5.9] 0.17
 Duration of surgery, h 3.7 [2.7, 4.7] 3.8 [3.0, 5.0] 0.16
 Crystalloid, l 1.5 [1, 2] 3.1 [2.2, 4.4] 1.26
 Colloid, l 1 [0.5, 1.5] 0.0 [0.0, 0.0] 4.78
 Number of boluses 4.0 [2.0, 5.5] 6.0 [3.0, 10.0] 0.61
 Blood given, ml 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.30
 Estimated blood lost, ml 300 [200, 625] 300 [200, 500]1 0.11
 Estimated urine output, ml 300 [200, 445] 300 [170, 500] 0.08
 Other fluids, ml 350 [200, 450] 400 [300, 500] 0.26
 Net fluids, l 2.46 [1.85, 3.3] 3.2 [2.1, 4.3] 0.51
 TWA MAP, mmHg 76.4 ± 8.334 74.6 ± 9.034 0.21
 End-tidal PCO
2
, % 34.2 ± 3.334 33.5 ± 3.234 0.20
 Final intraoperative core 
temperature, °C
37.0 ± 4.335 36.6 ± 0.635 0.13
 TWA FIO
2
, % 79.4 ± 1.834 79.4 ± 3.434 0.01
 MAC Hours 0.7 ± 0.534 0.7 ± 0.434 0.07
 Phenylephrine, mg 0.0 [0.0, 0.4] 0.1 [0.0, 0.6] 0.27
Summary statistics are presented as percentages of patients, means ± SD, or 
medians [quartile 1, quartile 3], respectively. Superscript numbers represent num-
ber of missing values.
*Absolute standardized difference: absolute difference in means or proportions 
divided by the pooled SD; ASD of 0.2, 0.5, and 0.8 represent small, median, and 
large differences.
APTT, partial thromboplastine time;  ASA, American Society of Anesthesiologists; ASD, 
absolute standardized difference; FIO
2
, fraction inspired oxygen concentration; MAC, min-
imum alveolar concentration, a measure of anesthetic dose; MAP, mean arterial pressure; 
PCO
2
, end-tidal partial pressure of carbon dioxide; PONV, postoperative nausea and vomit-
ing; PT, prothrommbin time; ST, ST-segment; TWA, time weighted average.
Appendix 9-2. Baseline and Intraoperative Characteristics 





(n = 403) ASD*
Age, yr 50.3 ± 15.8 50.5 ± 16.2 0.01
Body mass index, kg/m2 25.8 [22.3, 29.4] 25.6 [22.4, 29.0] 0.01
Female, no. (%) 185 (47) 198 (49) 0.04
ASA physical status, no. (%)   0.06
 I 24 (6)7 21 (5)1  
 II 220 (57) 222 (55)  
 III 144 (37) 159 (40)  
Race (white), no. (%) 369 (93) 378 (94) 0.02
Medical history, no. (%)    
 Pulmonary disease 34 (9)5 31 (8)7 0.03
 Cardiovascular disease 98 (25)1 114 (28) 0.08
 Neurologic disease 18 (5) 19 (5) 0.01
 Diabetes 29 (7)1 24 (6) 0.06
 Insulin use 9 (2) 7 (2)1 0.04
 History of PONV 29 (7)1 35 (9)1 0.05
 Alcohol (more than 25 drinks 
per week)
24 (6)1 27 (7)1 0.03
 Smoking status   0.13
   No 228 (58)1 252 (63)  
   Yes, currently 77 (20) 80 (20)  
   Yes, quit 89 (23) 70 (17)  
Preoperative bowel preparation   0.03
 Home 52 (13)4 56 (14)1  
 Hospital 78 (20) 76 (19)  
 None 261 (67) 270 (67)  
Preoperative lab    
 Creatinine, mg/dl 0.8 [0.7, 1.0]3 0.8 [0.7, 0.9]7 0.00
 Albumin, g/dl 4.3 [4.0, 4.7]92 4.3 [4.0, 4.7]103 0.03
 Hemoglobin, gm/dl 39.5 ± 5.43 39.4 ± 5.41 0.02
 Hematocrit, % 40.1 [37.5, 42.7]3 39.7 [36.8, 42.9]1 0.05
 Normotest/PT, s 89.1 [12.9, 110]230 88.5 [15.3, 105]245 0.04
 APTT STA, s 32.6 [29.0, 35.7]230 32.3 [29.8, 34.7]237 0.09
 Preoperative IV fluid per 
weight, ml/kg
5.7 [0.0, 7.5]26 5.6 [0.0, 7.8]28 0.01
Intraoperative variables    
 Duration of anesthesia, h 4.4 [3.3, 5.7] 4.4 [3.4, 5.6] 0.04
 Duration of surgery, h 3.2 [2.3, 4.4] 3.2 [2.3, 4.6] 0.06
 Crystalloid, l 1.85 [1.25, 2.4] 3.3 [2.33, 4.39] 0.61
 Colloid, l 1. 0 [0.5, 1.5]2 0.0 [0.0, 0.0]10 2.01
 Number of boluses 4.0 [2.0, 6.0] 5.0 [2.0, 8.0] 0.38
 Blood given, ml 0 [0, 0]8 0 [0, 0]10 0.00
 Estimated blood lost, ml 237 [100, 500]1 200.0 [100, 450] 0.03
 Estimated urine output, ml 340 [190, 550]4 350 [200, 500]6 0.03
 Other fluids, ml 0 [0, 350]36 0 [0, 450]40 0.03
 Net fluids, l 2.68 [1.87, 3.55] 3.2 [2.28, 4.38] 0.37
 TWA MAP, mmHg 80.7 ± 8.5 81.3 ± 8.5 0.07
 End-tidal PCO
2
, % 34.7 ± 2.11 34.4 ± 2.01 0.16
 Final intraoperative core 
temperature, °C
36.7 ± 3.1 36.7 ± 3.111 0.03
 TWA FIO
2
, % 65.4 ± 1 65.9 ± 21.71 0.02
 MAC, h 2.6 ± 2.83 2.5 ± 2.02 0.03
 Phenylephrine, mg 0.1 [0.0, 0.4] 0.1 [0.0, 0.6] 0.12
Summary statistics are presented as percentages of patients, means ± SD, or 
medians [quartile 1, quartile 3], respectively. Superscript numbers represents num-
ber of missing values.
*Absolute standardized difference: absolute difference in means or proportions 
divided by the pooled SD; ASD of 0.2, 0.5, and 0.8 represent small, median, and 
large differences.
APTT, partial thromboplastine time; ASA, American Society of Anesthesiologists; ASD, 
absolute standardized difference; FIO
2
, fraction inspired oxygen concentration; MAC, 
minimum alveolar concentration, a measure of anesthetic dose; MAP, mean arterial 
pressure; PCO
2
, end-tidal partial pressure of carbon dioxide; PONV, postoperative nausea 
and vomiting; PT, prothrommbin time; ST, ST-segment; TWA, time weighted average.
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